Sage Therapeutics’ experimental treatment for essential tremor, SAGE-324, has been dropped by its partner Biogen after a Phase II trial failed to meet its primary endpoint. Despite the setback, Sage Therapeutics will retain full ownership of SAGE-324 and explore potential alternative indications for the drug. Meanwhile, Sage Therapeutics and Biogen continue their collaboration on the depression drug Zurzuvae.